Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review

OBJECTIVE: Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene‐related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) must be reconsidered. Have previous ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaltseis, Katharina, Hamann, Till, Gaul, Charly, Broessner, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100419/
https://www.ncbi.nlm.nih.gov/pubmed/36437611
http://dx.doi.org/10.1111/head.14415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100419/
https://www.ncbi.nlm.nih.gov/pubmed/36437611
http://dx.doi.org/10.1111/head.14415

Ejemplares similares